**Multiple Myeloma in Depth: Answering questions on the management of MM patients**

**Hotel International Prague, Czech Republic**

**10–11 October 2019**

**Faculty: Prof Michel Delforge, Belgium; Prof Xavier Leleu, France; Dr Faith Davies, USA; Dr Roman Hàjek, Czech Republic**

**DRAFT AGENDA – DAY 1**

|  |  |  |
| --- | --- | --- |
| **TIME** | **ITEM** | **SPEAKER** |
| **12:45–13:15** | **WELCOME AND INTRODUCTION****NAVIGATING THE MM TREATMENT LANDSCAPE** | **M Delforge** **R Hajek** |
| 30min plenary presentation and Q&A | * Welcoming of delegates and overview of faculty and key goals of the meeting

Introduction session:* MM mode of disease and importance of targeting the immune microenvironment
* Evolving treatment landscape:
	+ from duplets to triplets
	+ Incorporation of new treatment options in guidelines
		- Evolving ESMO guidelines (2013 and 2017)
		- New combination therapies (approved after publication of ESMO guidelines)
 | Plenary |
| **13:15–14:15** | **SESSION 1: CONSIDERATIONS FOR THE TREATMENT OF NDMM PATIENTS**  | **M Delforge** |
| 15min plenary presentation and Q&A | * Considerations, challenges and current management of NDMM patients
* Discuss the treatment objectives for different NDMM patients
* Remind the attendees of the key factors and challenges associated with treatment decisions for NDMM patients
	+ Disease-, patient- and treatment-related
 | Plenary |
| 45min workshop: Current practice in the management of NDMM | Objectives* Review and discuss current management strategies
* Reflect on key selection criteria for treatment decisions

Format* Each delegate table works as a group using a workmat

How does it work? * Each group is provided a workmat with a set of questions
* The groups fill in the profile with patient characteristics, using ‘typical’ patients, one eligible and one non-eligible for transplant
* They identify key patient characteristics that affect treatment strategy
* They discuss how they would treat such patients using currently available options and note this management strategy
* They discuss the questions provided as a group
* Faculty will choose two groups to present for wider group discussion
* Faculty close – focus on key patient characteristics and current management strategies, with summary of key learnings from session
 | All faculty  |
| **14:15–15:30** | **SESSION 2: CURRENT TREATMENT OPTIONS FOR NSCT NDMM PATIENTS** | **X Leleu** |
| 50min plenary presentation+ 25min Q&A | * Overview of guidelines and recommendations for the treatment of NSCT NDMM patients
* The rationale for investigating RVd in NSCT NDMM
* Presentation of the SWOG S0777 trial clinical data
* Discuss how the SWOG S0777 clinical data translate into the treatment of patients in clinical practice using a patient case
* The rationale for investigating Rd in NSCT NDMM
* Presentation of MM-020 trial clinical data
	+ Efficacy and safety of ITT population
	+ Including selected key subgroup analysis data
* Discuss how the MM-020 clinical data translate into the treatment of patients in clinical practice using a patient case
 | Plenary |
| **15:30–16:00** | **COFFEE BREAK** |  |
| **16:00–18:00** | **BREAKOUT SESSION 1: MANAGEMENT OF CONTINUOUS THERAPY IN NDMM** | **All faculty** |
| 60min | Topic* Treatment selection – how to select and adapt treatment according to patient and disease characteristics

Format* Breakouts in three groups
* Relevant data and guidelines presentation
* Including discussion of selecting treatments (doublets vs triplets) and adapting treatment doses and schedules
* 2–3 case discussions
 | Breakouts |
| 60min | Topic* Keeping patients on treatment – from prophylaxis to AE management

*Same format as above** Including discussion of management of treatment schedules and AEs
 | Breakouts |
| **19:30–22:00** | **DINNER** | **All**  |

**DRAFT AGENDA – DAY 2**

|  |  |  |
| --- | --- | --- |
| **TIME** | **ITEM** | **SPEAKER** |
| **08:15–08:30** | **WELCOME TO DAY 2** | **M Delforge** |
| **08:30–09:00** | **SESSION 3: MAINTENANCE TREATMENT MANAGEMENT AFTER TRANSPLANT**  | **F Davies** |
| 20min plenary presentation+ 10min Q&A | * Overview of guidelines and recommendations for the treatment of NDMM patients eligible for transplant
* Remind the audience of the rationale and objectives of maintenance treatment
* Presentation of data from trials investigating maintenance (CALGB, IFM, GIMEMA, Myeloma XI, Meta-Analysis)
	+ Efficacy and safety
* Discuss how the clinical data translate into the treatment of patients in clinical practice using a patient case
 | Plenary |
| **09:00–10:00** | **SESSION 4: TREATMENT OF RRMM PATIENTS**  | **F Davies** |
| 40min plenary presentation and case discussion+ 20min Q&A | * Briefly review key considerations impacting treatment decision at relapse
* Overview of the approved treatment options at first relapse (considering first line treatment)
	+ PVd as an option for patients who received ≥1 prior line of therapy including lenalidomide
		- Review of MM-007 data
* Present the different clinical situations at relapse following lenalidomide treatment in frontline (on/off treatment, dose, clinical/biochemical relapse…) and discuss their implications on treatment decision
* Review guidelines recommendations
 | Plenary |
| **10:00–10:30** | **COFFEE BREAK** |  |
| **10:30–12:00** | **BREAKOUT SESSION 2: CASE DISCUSSION** | **All faculty** |
| 90min | *Attendees will be requested to bring some cases for discussions as breakouts*Topics* NDMM patients
* RRMM patients
 | Breakouts |
| **12:00–13:00** | **LUNCH BREAK** |  |
| **13:00–14:00** | **SESSION 5: THE PARADIGM OF TREATMENT IN MM: NOW AND IN THE FUTURE** | **All faculty** |
| 60min panel discussion and audience Q&A | * Potential topics to include:
	+ Discussion of SWOG S0777 and MM-007 data
	+ Future perspectives in the management of patients with MM, e.g.:
		- Tailoring treatment
		- Incorporation of MRD assessment in clinical practice
		- Remaining unmet needs in patients with MM
		- Incorporation of diagnostic tools (i.e. PET imaging)
 | Panel discussion / Q&A  |
| **14:00–14:15** | **SUMMARY AND CLOSE**  | **M Delforge** All faculty |